BioThrax Anthrax Vaccine Description
BioThrax, Anthrax Vaccine Adsorbed, is made from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis.
BioThrax is intended to stimulate the production of neutralizing antibodies that recognize the vaccine antigens, protective antigen (PA), lethal factor, and edema factor and are expected to be protective against Bacillus anthracis infection.
The efficacy of BioThrax has not been evaluated through clinical trials. Vaccine efficacy has been inferred from immunogenicity data, including anti-PA IgG and toxin neutralization titers.
Gaithersburg, Maryland-based Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life.
BioThrax Anthrax Vaccine Indication
BioThrax is a vaccine indicated for active immunization to prevent disease caused by Bacillus anthracis in persons 18 through 65 years of age whose occupation or other activities place them at high risk of exposure.
BioThrax Anthrax Vaccine Dosage
BioThrax Anthrax Vaccine consists of 3-doses each of 0.5 mL, given at 0, 1, and 6 months. Booster: 0.5 mL at three-year intervals OR as per official recommendations. The vaccine is given by deep intramuscular (IM) injection in the deltoid region.
BioThrax is administered either as a deep intramuscular injection in the deltoid region.
BioThrax Anthrax Vaccine News
July 30, 2019 - Emergent BioSolutions Inc. announced that the Biomedical Advanced Research and Development Authority (BARDA) had exercised its first contract option valued at $261 million to procure doses of AV7909 (BioThrax adsorbed with adjuvant) for delivery into the Strategic National Stockpile (SNS) over 12 months.
December 17, 2018 - Emergent BioSolutions Receives Health Canada Approval of BioThrax®
March 17, 2017 - Emergent BioSolutions Awarded $100 Million BARDA Contract for BioThrax Deliveries to the Strategic National Stockpile.
BioThrax Anthrax Vaccine Clinical Trials
Clinical Trial NCT01641991: A Phase 4 Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax AVA Schedule
Clinical Trial NCT03877926: VELOCITY: An Anthrax Vaccine Phase 3 Clinical Study
Clinical Trial NCT01770743: A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels